Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.
We have tested, in a prospective randomized, double-blind, placebo-controlled, crossover, 12-week study, the effects of 2 mg efaroxan, a potent alpha-2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha-2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.
Rascol
O
O
Department of Clinical Pharmacology, University Hospital, Toulouse, France.
Sieradzan
K
K
Peyro-Saint-Paul
H
H
Thalamas
C
C
Brefel-Courbon
C
C
Senard
J M
JM
Ladure
P
P
Montastruc
J L
JL
Lees
A
A
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001572:Benzofurans / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D011446:Prospective Studies; D013494:Supranuclear Palsy, Progressive / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D001572:Benzofurans; D007093:Imidazoles; C062597:efaroxan